Trial reportBritish journal of haematology2013
Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.
Trial report in British journal of haematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Use of rituximab in mature, high-grade and advanced-stage pediatric B-lineage non-Hodgkin lymphomas: a systematic review, meta-analysis and the Brazilian reality.Frontiers in pediatrics · 2025Pooled it
- Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.The New England journal of medicine · 2020Trial
- Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.British journal of haematology · 2014Trial
- A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Trial
- Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review.Pediatric nephrology (Berlin, Germany) · 2024Review
- Review
- Article
- Outcomes of Burkitt lymphoma with bone marrow involvement or Burkitt leukemia in Chinese children.Pediatric investigation · 2021Article
- Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.Current hematologic malignancy reports · 2019Review
- Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases.British journal of clinical pharmacology · 2019Article
- Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.British journal of haematology · 2018Article
- Article
- Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.British journal of haematology · 2017Article
- Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Clinical pharmacokinetics · 2015Review
- [Malignant lymphomas in children and adolescents. Practical knowledge for diagnosis].Der Pathologe · 2014Review
- DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.Journal of clinical and experimental hematopathology : JCEHArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 1 country.
Funding
Abstract
The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.